Vasodilatory Nicorandil Powder CAS 65141-46-0 Slight Odour

Product Description

Nicorandil JP EP CP CAS No. 65141-46-0 Vasodilatory

Nicorandil, a drug approved for the treatment of ischaemic heart disease, is believed to have a dual properties.

High purity 98% above and goods in stock. 

stored at 2~8℃

Nicorandil is a vasodilatory drug used to treat angina.

Angina is chest pain that results from episodes of transient myocardial ischemia. This can be caused by diseases such as atherosclerosis, coronary artery disease and aortic stenosis. Angina commonly arises from vasospasm of the coronary arteries. There are multiple mechanisms causing the increased smooth muscle contraction involved in coronary vasospasm, including increased Rho-kinase activity. Increased levels of Rho-kinase inhibit myosin phosphatase activity, leading to increased calcium sensitivity and hypercontraction. Rho-kinase also decreases nitric oxide synthase activity, which reduces nitric oxide concentrations. Lower levels of nitric oxide are present in spastic coronary arteries. L-type calcium channel expression increases in spastic vascular smooth muscle cells, which could result in excessive calcium influx, and hypercontraction.

Who we are:

XI’AN LIBANG PHARMACEUTICAL CO.,LTD. founded in 1996 with a location in Xi’an City of China, the center of the northwest pharmaceutical industry, is specialized in research, development, production and distribution of specialty pharmaceutical products. As the first and also largest supplier of generic Propofol in China, LIBANG started its business and subsequently launched a broad portfolio finished dosage forms covering anesthetics, cardiovascular, antineoplastic, clinical nutrition etc.

With more than 20 years growth, LIBANG has transformed into an integrated health care solution provider, LIBANG HEALTHCARE GROUP, with diversified fields covering high value-added APIs, pharmaceutical excipients, prescription drugs, OTC products, biomedicine, medical devices.

LIBANG is a technology-driven firm, with more than 8% of the annual sales revenues devoted to research and innovation, establishing a unique R&D platform to proactively follow the latest pharmaceutical technology frontier.

LIBANG now is one of Top 100 China’s Pharmaceutical Industries and also listed in the Top 20 The Most Potential Chinese Pharmaceuticals that was rated by the IMS Health.